Active, not recruitingNCT03853486
ATHN 9: Severe VWD Natural History Study
Studying Von Willebrand disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- American Thrombosis and Hemostasis Network
- Principal Investigator
- Robert Sidonio, MDEmory University / Children's Healthcare of Atlanta
- Enrollment
- 108 target
- Eligibility
- All sexes
- Timeline
- 2019 – 2026
Study locations (22)
- Center for Inherited Blood Disorders, Orange, California, United States
- University of Colorado Denver Hemophilia and Thrombosis Center, Aurora, Colorado, United States
- Connecticut Bleeding and Clotting Disorders Center, Farmington, Connecticut, United States
- University of Florida Hemophilia Treatment Center, Gainesville, Florida, United States
- Children's Healthcare of Atlanta/Emory, Atlanta, Georgia, United States
- Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
- Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, Indiana, United States
- Louisiana Center for Bleeding and Clotting Disorders, New Orleans, Louisiana, United States
- University of Michigan Hemophilia and Coagulation Disorders, Ann Arbor, Michigan, United States
- Children's Hospital of Michigan Hemostasis and Thrombosis Center, Detroit, Michigan, United States
- Michigan State University Center for Bleeding and Clotting Disorders, East Lansing, Michigan, United States
- Mayo Comprehensive Hemophilia Center, Rochester, Minnesota, United States
- Washington University Center for Treatment of Bleeding and Blood Clotting Disorders, St Louis, Missouri, United States
- Nationwide Children's Hospital Columbus, Columbus, Ohio, United States
- Oregon Health, Portland, Oregon, United States
- +7 more locations on ClinicalTrials.gov
Collaborators
Takeda
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03853486 on ClinicalTrials.govOther trials for Von Willebrand disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07404644An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT07115004Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)Vega Therapeutics, Inc
- RECRUITINGPHASE3NCT07129343A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06998524A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseHoffmann-La Roche
- RECRUITINGNCT06883240An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentHoffmann-La Roche
- RECRUITINGPHASE3NCT05582993A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06205095A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWDUnity Health Toronto
- RECRUITINGPHASE1, PHASE2NCT05776069Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)Vega Therapeutics, Inc